← Leaderboards
Steven Estus
University Of Kentucky
$7,615,797
Attributed
$10,221,864
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2006–24$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,221,864 · 10
By mechanism
RF1$3,909,100 · 1
R01$3,267,913 · 4
P01$1,420,122 · 1
R21$836,376 · 2
R56$610,216 · 1
P50$178,137 · 1
Top collaborators
- Mary Beth Humphrey2 shared
- William Garrow Kerr2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Guangxiang George Luo$12,758,769
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseGeneticProtein IsoformsGenetic PolymorphismSingle Nucleotide PolymorphismBrainAllelesProteinsRna SplicingExonsIn VivoIn VitroS Disease RiskReceptorVariantGenotypeLengthGene ExpressionApolipoprotein EMediatingBaseGenesRelative (Related Person)
Grant awards (25)
Deciphering genetics of PLCG2 alternative splicing to understand AD risk$415,626
R21 · FY2024 · AG · contact PI
How does D2-CD33 reduce Alzheimer's disease risk?$420,750
R21 · FY2020 · AG · contact PI
Translating SHIP1 Genetics to Generate a Novel Alzheimers Pharmacologic Agent$118,080
RF1 · FY2019 · AG · contact PI
Translating SHIP1 genetics to generate a novel Alzheimer's pharmacologic agent$3,791,020
RF1 · FY2018 · AG · contact PI
The surprising impact of APOE alleles on gut microbiome: does altering the microbiome reduce AD risk?$610,216
R56 · FY2018 · AG · contact PI
Translating CD33 genetic mechanism into a novel Alzheimers therapeutic$307,490
R01 · FY2017 · AG · contact PI
Translating CD33 genetic mechanism into a novel Alzheimers therapeutic$307,490
R01 · FY2016 · AG · contact PI
Translating CD33 genetic mechanism into a novel Alzheimers therapeutic$298,018
R01 · FY2015 · AG · contact PI
Translating CD33 genetic mechanism into a novel Alzheimers therapeutic$306,475
R01 · FY2014 · AG · contact PI
APOE RECEPTOR SPLICING, GENETICS, AND AD$261,550
P01 · FY2013 · AG · contact PI
APOE RECEPTOR SPLICING, GENETICS, AND AD$277,176
P01 · FY2012 · AG · contact PI
APOE RECEPTOR SPLICING, GENETICS, AND AD$286,846
P01 · FY2011 · AG · contact PI
APOE RECEPTOR SPLICING, GENETICS, AND AD$290,222
P01 · FY2010 · AG · contact PI
APOE RECEPTOR SPLICING, GENETICS, AND AD$304,328
P01 · FY2009 · AG · contact PI
LDLR Genetics, Splicing and AD Risk$137,668
R01 · FY2009 · AG · contact PI
LDLR Genetics, Splicing and AD Risk$257,497
R01 · FY2008 · AG · contact PI
LDLR Genetics, Splicing and AD Risk$262,752
R01 · FY2007 · AG · contact PI
LDLR Genetics, Splicing and AD Risk$282,225
R01 · FY2006 · AG · contact PI
UPA Polymorphisms as a Differential Risk Factor for AD$253,400
R01 · FY2004 · AG
Urokinase-type plasminogen activator and Alzheimer's$103,960
R01 · FY2004 · AG
UPA Polymorphisms as a Differential Risk Factor for AD$253,400
R01 · FY2003 · AG
Urokinase-type plasminogen activator and Alzheimer's$100,686
R01 · FY2003 · AG
UPA Polymorphisms as a Differential Risk Factor for AD$253,400
R01 · FY2002 · AG
Urokinase-type plasminogen activator/Alzheimer's Disease$143,452
R01 · FY2002 · AG
Novel peptide inhibitors of A beta accumulation &action$178,137
P50 · FY2000 · AG